SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
President Donald Trump listens as Dr. Moncef Slaoui, the former head of GlaxoSmithKlines vaccines division, speaks about coronavirus vaccine development in the Rose Garden of the White House on May 15, 2020. (Photo: Drew Angerer/Getty Images)
Trump's Vaccine Chief Picks His Own Former Employer--Where He Still Holds Millions Worth of Stock--for $2.1 Billion Deal
"You can't have a contractor supervising government officials."
Jul 31, 2020
The White House on Friday awarded a record-breaking $2.1 billion contract for development of a Covid-19 vaccine, raising questions about a former pharmaceutical executive's involvement in the administration's decision.
The deal is for 100 million doses of a vaccine manufactured by Sanofi, a French drug maker, and its British partner GlaxoSmithKline (GSK).
As Fortunereported:
The deal follows billions of dollars of U.S. commitments to other experimental vaccines--all still needing to show their effectiveness in testing--and may stoke concerns that other countries will be left behind. Vaccines are seen as the key to leading the world out of the pandemic that has killed about 675,000 people in a matter of months.
Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine. Slaoui's connection to his former company has been the focus of concern from advocacy groups and politicians skeptical of his claims of neutrality.
According to the New York Times:
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sen. Elizabeth Warren (D-Mass.) raised concerns over Slaoui's ties to GSK in May.
"It is a huge conflict of interest for the White House's new vaccine czar to own $10 million of stock in a company receiving government funding to develop a Covid-19 vaccine," Warren tweeted. "Dr. Slaoui should divest immediately."
As Common Dreams reported, the former executive's refusal to relinquish his shares in the company made the process of awarding a contract a "sham," in the words of former Office of Government Ethics director Walter Shaub.
"You can't have a contractor supervising government officials," said Shaub.
Join Us: News for people demanding a better world
Common Dreams is powered by optimists who believe in the power of informed and engaged citizens to ignite and enact change to make the world a better place. We're hundreds of thousands strong, but every single supporter makes the difference. Your contribution supports this bold media model—free, independent, and dedicated to reporting the facts every day. Stand with us in the fight for economic equality, social justice, human rights, and a more sustainable future. As a people-powered nonprofit news outlet, we cover the issues the corporate media never will. |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
The White House on Friday awarded a record-breaking $2.1 billion contract for development of a Covid-19 vaccine, raising questions about a former pharmaceutical executive's involvement in the administration's decision.
The deal is for 100 million doses of a vaccine manufactured by Sanofi, a French drug maker, and its British partner GlaxoSmithKline (GSK).
As Fortunereported:
The deal follows billions of dollars of U.S. commitments to other experimental vaccines--all still needing to show their effectiveness in testing--and may stoke concerns that other countries will be left behind. Vaccines are seen as the key to leading the world out of the pandemic that has killed about 675,000 people in a matter of months.
Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine. Slaoui's connection to his former company has been the focus of concern from advocacy groups and politicians skeptical of his claims of neutrality.
According to the New York Times:
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sen. Elizabeth Warren (D-Mass.) raised concerns over Slaoui's ties to GSK in May.
"It is a huge conflict of interest for the White House's new vaccine czar to own $10 million of stock in a company receiving government funding to develop a Covid-19 vaccine," Warren tweeted. "Dr. Slaoui should divest immediately."
As Common Dreams reported, the former executive's refusal to relinquish his shares in the company made the process of awarding a contract a "sham," in the words of former Office of Government Ethics director Walter Shaub.
"You can't have a contractor supervising government officials," said Shaub.
The White House on Friday awarded a record-breaking $2.1 billion contract for development of a Covid-19 vaccine, raising questions about a former pharmaceutical executive's involvement in the administration's decision.
The deal is for 100 million doses of a vaccine manufactured by Sanofi, a French drug maker, and its British partner GlaxoSmithKline (GSK).
As Fortunereported:
The deal follows billions of dollars of U.S. commitments to other experimental vaccines--all still needing to show their effectiveness in testing--and may stoke concerns that other countries will be left behind. Vaccines are seen as the key to leading the world out of the pandemic that has killed about 675,000 people in a matter of months.
Dr. Moncef Slaoui, a former GSK executive, is head of the White House's Operation Warp Speed, the administration's program to develop and disburse an effective coronavirus vaccine. Slaoui's connection to his former company has been the focus of concern from advocacy groups and politicians skeptical of his claims of neutrality.
According to the New York Times:
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sen. Elizabeth Warren (D-Mass.) raised concerns over Slaoui's ties to GSK in May.
"It is a huge conflict of interest for the White House's new vaccine czar to own $10 million of stock in a company receiving government funding to develop a Covid-19 vaccine," Warren tweeted. "Dr. Slaoui should divest immediately."
As Common Dreams reported, the former executive's refusal to relinquish his shares in the company made the process of awarding a contract a "sham," in the words of former Office of Government Ethics director Walter Shaub.
"You can't have a contractor supervising government officials," said Shaub.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.